2019.01.18
License Agreement Has Been Entered with Thyas Co. Ltd.
License-Out
We executed a worldwide license agreement with Thyas Co. Ltd. (Kyoto, Japan) for the use of iPS cell-derived T cells for autologous immunotherapy of cancers and infectious diseases, the license allowing exclusive rights on patents related to T cell induction and non-exclusive rights on the patents related to iPS cell technology and, for all of which sublicensing rights have been granted to us by Kyoto University.